The SLBT SEC filings page on Stock Titan is intended to provide access to regulatory documents associated with SL Science Holding Limited, the post-business combination holding company tied to SL BIO Ltd. and Horizon Space Acquisition II Corp. SLBT is expected to be the Nasdaq ticker symbol for this holding company if the proposed business combination is completed and listing conditions are met.
For this transaction, a registration statement on Form F-4 has been declared effective by the U.S. Securities and Exchange Commission. That document, together with the accompanying proxy statement/prospectus, describes the terms of the business combination between SL BIO Ltd., a biomedical company focused on cellular and gene therapies, and Horizon Space Acquisition II Corp., a special purpose acquisition company (SPAC). Once available under the SLBT symbol, SEC filings can include registration statements, periodic reports, and other disclosures relating to the combined company.
Stock Titan enhances these filings with AI-powered summaries that are designed to highlight key sections of lengthy documents. For example, when SLBT files annual reports on Form 10-K or foreign private issuer equivalents, quarterly reports on Form 10-Q (if applicable), or current reports on Form 8-K, the platform can surface major risk factors, business descriptions, and transaction updates in a more accessible format.
In addition, when insider transaction reports on Form 4 or other ownership-related filings become available for SLBT, this page will organize them alongside other SEC submissions. Real-time updates from the EDGAR system and AI-assisted explanations help users quickly understand the regulatory information that shapes the SLBT investment profile.
SL Science Holding Ltd filed an initial Form 3 for director Liu Mingche. This filing serves as the first statement of beneficial ownership for this insider and establishes a baseline record of their reporting status with no transactions disclosed in this document.
SL Science Holding Ltd director Chen Kwo-Liang has filed an initial Form 3, which is a required statement of beneficial ownership for insiders. The filing lists his status as a director of the company but does not report any current holdings or recent transactions in SLBT securities.
SL Science Holding Ltd director General John Conrad filed an initial ownership report on Form 3. This filing identifies him as a director and reporting person for SLBT but shows no reported stock or derivative holdings and no buy, sell, or other insider transactions.
SL Science Holding Ltd filed an initial Form 3 for Chief Financial Officer Leung Lok Sang. This filing reports no insider transactions or derivative positions, with all buy, sell, exercise, and other transaction counts shown as zero in the summary data.
SL Science Holding Ltd filed a Form 3 for director Joseph Levinson, which is an initial statement of beneficial ownership for insiders. The filing’s transaction summary shows no buys, sells, gifts, exercises, or other transactions and no derivative positions in this excerpt.
SL Science Holding Limited has completed its business combination between SL BIO Ltd. and Horizon Space Acquisition II Corp., creating a Cayman Islands holding company whose ordinary shares are expected to begin trading on the Nasdaq Global Market under the ticker “SLBT” on June 15, 2026.
The transaction carries an implied equity valuation for SL Bio of approximately $5.568 billion and includes a concurrent $7.8 million PIPE financing, providing additional capital for its cell and gene therapy platform. SL Science has also installed a public‑company leadership team, led by CEO William Wang and CFO Ray Leung, and formed a board with multiple independent directors experienced in accounting, investment banking, regulatory compliance, and scientific oversight.